NCT04398680View on ClinicalTrials.gov

A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function

PHASE1RecruitingINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

April 20, 2021

Primary Completion Date

October 13, 2025

Study Completion Date

October 13, 2025

Conditions

Multiple Myeloma

Interventions

DRUG

Belantamab mafodotin

Belantamab mafodotin will be administered

Trial Locations (2)

49241

RECRUITING

GSK Investigational Site, Pusan

85724

RECRUITING

GSK Investigational Site, Tucson

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT04398680 - A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function | Biotech Hunter | Biotech Hunter